secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001641172-25-019645
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC
--------------------------------------------------------------------------------

- No dose-limiting toxicities or unexpected adverse events in first 10 patients.
- No Grade 3 or 4 toxicities observed; side effects manageable with standard care.
- Phase 2 trial to enroll 100 patients; interim efficacy data expected September 2025.
- Company plans to discuss potential pivotal Phase 3 study design with regulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225019645/0001641172-25-019645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225019645/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-019645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer